Quinoxaline compounds as hypnotic agents

Claim 3

The method of claim 1 wherein the warm-blooded animal is a human being.

Claim 4

The method of claim 2 wherein the active agent is 6-trifluoromethyl-2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 5

The method of claim 3 wherein the active agent is 6-trifluoromethyl-2(1H), 3(4H)-quinoxalinedione.

Claim 6

The method of claim 3 wherein the active agent is 6-trifluoromethyl-2(1H), 3(4H)-quinoxalinedione monopotassium salt.

Claim 7

The method of claim 2 wherein the active agent is 6-methyl-2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 8

The method of claim 2 wherein the active agent is 6-ethyl-2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 9

The method of claim 2 wherein the active agent is 5-methyl-2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 10

The method of claim 2 wherein the active agent is 2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 13

fluoroalkyl of C 1 -C 2 , 11. amino, or 12. amino mono or disubstituted with loweralkyl of C 1 -C 4 , each independently selected; subject to the limitation that R can represent bromo or chloro only when n represents 2 and one R represents a moiety other than bromo or chloro; and R 1 represents 1. H or 2. methyl; and a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 14

fluoroalkyl of C 1 -C 2 , 11. amino, or 12. amino mono or disubstituted with loweralkyl of C 1 -C 4 , each independently selected; subject to the limitation that R can represent bromo or chloro only when n represents 2 and one R represents a moiety other than bromo or chloro; and R 1 represents 1. H or 2. methyl; and a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 15

The method of claim 10 wherein the warm-blooded animal is a human being.

Claim 16

The method of claim 11 wherein the active agent is 6-trifluoromethyl-2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 17

The method of claim 12 wherein the active agent is 6-trifluoromethyl-2(1H), 3(4H)-quinoxalinedione.

Claim 18

The method of claim 12 wherein the active agent is 6-trifluoromethyl-2(1H), 3(4H)-quinoxalinedione monopotassium salt.

Claim 19

The method of claim 11 wherein the active agent is 6-methyl-2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 20

The method of claim 11 wherein the active agent is 6-ethyl-2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 21

The method of claim 11 wherein the active agent is 5-methyl-2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 22

The method of claim 11 wherein the active agent is 2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 23

A pharmaceutical formulation in dosage unit form adapted for administration to obtain a hypnotic effect, comprising per dosage unit, a hypnotically-effective non-toxic amount within the range from about 10 to about 1000 milligrams of at least one active agent selected from the group consisting of a compound of the formula ##SPC16## wherein n represents 0, 1, or 2; each R independently represents 1. loweralkyl of C 1 -C 4 , 2. loweralkoxy of C 1 -C 4 , 3. loweralkylthio of C 1 -C 4 , 4. cyclopropyl, 5. bromo, 6. chloro, 7. fluoro, 8. nitro, 9. cyano, 10. fluoroalkyl of C 1 -C 2 , 11. amino, or 12. amino mono or disubstituted with loweralkyl of C 1 -C 4 , each independently selected; subject to the limitation that R can represent bromo or chloro only when n represents 2 and one R represents a moiety other than bromo or chloro; and R 1 represents 1. H or 2. methyl; and a pharmaceutically acceptable alkali metal or alkaline earth metal salt and a pharmaceutically acceptable carrier therefor.

Claim 24

A pharmaceutical formulation in dosage unit form adapted for administration to obtain a hypnotic effect, comprising per dosage unit, a hypnotically-effective non-toxic amount within the range from about 10 to about 1000 milligrams of at least one active agent selected from the group consisting of a compound of the formula ##SPC16## wherein n represents 0, 1, or 2; each R independently represents 1. loweralkyl of C 1 -C 4 , 2. loweralkoxy of C 1 -C 4 , 3. loweralkylthio of C 1 -C 4 , 4. cyclopropyl, 5. bromo, 6. chloro, 7. fluoro, 8. nitro, 9. cyano, 10. fluoroalkyl of C 1 -C 2 , 11. amino, or 12. amino mono or disubstituted with loweralkyl of C 1 -C 4 , each independently selected; subject to the limitation that R can represent bromo or chloro only when n represents 2 and one R represents a moiety other than bromo or chloro; and R 1 represents 1. H or 2. methyl; and a pharmaceutically acceptable alkali metal or alkaline earth metal salt and a pharmaceutically acceptable carrier therefor.

Claim 25

The formulation of claim 19 wherein the active agent is 6-trifluoromethyl-2(1H), 3(4H)-quinoxalinedione or a pharmaceutically acceptable alkali metal or alkaline earth metal salt.

Claim 26

The formulation of claim 20 wherein the active agent is 6-trifluoromethyl-2(1H), 3(4H)-quinoxalinedione.

Claim 27

The formulation of claim 20 wherein the active agent is 6-trifluoromethyl-2(1H), 3(4H)-quinoxalinedione monopotassium salt.